



ASX Release

30 March 2017

**ZELDA THERAPEUTICS LIMITED**  
**ACN 103 782 378**

Level 45  
108 St Georges Terrace,  
Perth Western Australia 6000  
Tel: +61 8 6558 0886  
Fax: +61 8 6316 3337  
E: [enquiries@zeldatherapeutics.com](mailto:enquiries@zeldatherapeutics.com)  
Web: [www.zeldatherapeutics.com](http://www.zeldatherapeutics.com)

#### **Contacts**

##### **Corporate**

Mr Harry Karelis  
Executive Chairman  
+61 413 056 328  
[hkarelis@zeldatherapeutics.com](mailto:hkarelis@zeldatherapeutics.com)

##### **Investors**

Dr Stewart Washer  
Executive Director  
+61 418 288 212  
[swasher@zeldatherapeutics.com](mailto:swasher@zeldatherapeutics.com)

##### **Directors**

Mr Harry Karelis  
Dr Stewart Washer  
Ms Mara Gordon  
Mr Jason Peterson

##### **ASX Code:**

ZLD

##### **Ordinary Shares:**

669,127,649

##### **Options:**

48,000,000

6,000,000 (\$0.04 - 6/2/2020 -  
subject to vesting conditions)  
2,000,000 (\$0.04 - 6/2/2020)  
40,000,000 (\$0.03125-17/11/2021)

## **Zelda Therapeutics Successfully Completes Oversubscribed Capital Raising of A\$6,000,000**

### **Highlights**

- ) **Zelda Therapeutics has placed 85,714,286 shares at A\$0.07 per share to raise A\$6 million**
- ) **The Placement was significantly oversubscribed with strong support from new Australasian institutional investors**
- ) **The Placement has been made utilising ASX Listing Rule 7.1 placement capacity**
- ) **The funds will be used to accelerate and expand research and clinical programmes**

The Board of **Zelda Therapeutics Ltd (ASX: ZLD, Zelda or the Company)** is pleased to announce it has successfully completed a placement of 85,714,286 million fully-paid ordinary shares at a share price of \$0.07, for gross proceeds of \$6.0 million before costs ("Placement"). There was strong support from new institutional investors in Australia and Hong Kong, adding further strength to Zelda's share registry.

The Placement was heavily over-subscribed, and settlement is expected to occur on 4 April with the shares to be issued shortly thereafter. The Placement shares will be issued under the Company's existing 15% placement capacity under ASX Listing Rule 7.1, and accordingly will not require shareholder approval.

The Placement will increase the Company's cash position to approximately \$8.3 million before costs, providing sufficient financial capacity for Zelda to execute its current research programmes and pursue new opportunities to grow its clinical pipeline for the development of new medicinal cannabis therapies in Australia and Chile. In-line with the Company's business strategy, Zelda Therapeutics is focused on delivering world-class research to clinically prove the benefits of medical cannabis for specific disease targets, with a clear commercialisation pathway to drive maximum shareholder value.

The Placement is being managed by Merchant Corporate Advisory Pty Ltd, recognised as leaders in financing the medicinal cannabis space, along with clients of CPS Capital Group Pty Ltd participating.

### **Placement Timetable**

Event	Date
Placement Settlement via DvP*	Tuesday, 4 April 2017
Quotation of Placement Shares	Wednesday, 5 April 2017

*Note – the above timetable is indicative only and subject to change.*

*\* DVP (Delivery v Payment) is the irrevocable exchange of unconditional financial products for unconditional same day funds.*

**Tim Slate**  
**Company Secretary**

**About Zelda Therapeutics ([www.zeldatherapeutics.com](http://www.zeldatherapeutics.com))**

Zelda Therapeutics (“Zelda”) is an Australian-based bio-pharmaceutical company that has secured exclusive, global access to an extensive set of human data related to medicinal cannabis based formulations and treatment protocols. This human data has been generated over several years by a California-based group (*Aunt Zelda’s*) that has a very high profile within the USA and a growing international profile based upon its deep knowledge of the scientific rationale for certain cannabis-based formulations and protocols to treat a variety of medical conditions.

Zelda has embarked on a programme of human clinical trials initially in sleep disorder (insomnia) and eczema indications.

In addition, Zelda is building a pre-clinical research portfolio targeting cancer. It has partnered with the world’s leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer.